<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060315233229+01'00'</creation_date><modification_date>D:20060315233229+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-99-100_h_a_dec_4.pdf</pdf_file></head><body><section><header>en</header><p>commission of the european communities brussels, 20.09.2001 c(2001) 2734</p></section><section><header>not for publication commission decision 
  of 20.09.2001 
 amending decision c(1999) 939 on the marketing authorisation for the medicinal 
 product for human use</header></section><section><header>&quot;cetrotide - cetrorelix (as acetate)&quot;</header></section><section><header>(text with eea relevance)</header><p>only the english text is authentic</p><p> iii</p></section><section><header>commission decision of 20.09.2001 
 amending decision c(1999) 939 on the marketing authorisation for the medicinal 
 product for human use</header></section><section><header>&quot;cetrotide - cetrorelix (as acetate)&quot;</header></section><section><header>(text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community, 
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorisation and supervision of medicinal products for human 
 and veterinary use and establishing a european agency for the evaluation of medicinal 
 products,
 1 as amended by commission regulation (ec) no 649/98,2</p><p>having regard to commission regulation (ec) no 542/95 of 10 march 1995 concerning the examination of variations to the terms of a marketing authorisation falling within the scope of 
 council regulation (eec) no 2309/93,
 3 as amended by commission regulation (ec) no 1069/98,
 4 and in particular article 8(3) thereof, having regard to the opinion of the european agency for the evaluation of medicinal 
 products, 
 whereas: 
 (1)</p><p>the medicinal product 
 &quot;cetrotide - cetrorelix (as acetate)&quot; entered in the community register of medicinal products under no(s) eu/1/99/100/001-003 authorised by 
 commission decision c(1999) 939 of 13 april 1999, as amended, complies with the 
 requirements set out in regulation (eec) no 2309/93. 
 (2)</p><p>ares-serono (europe) ltd submitted an application on 26 january 2001 pursuant to 
 article 6(1) of regulation (ec) no 542/95. 
 (3)</p><p>the european agency for the evaluation of medicinal products delivered the 
 favourable opinion formulated on 31 may 2001 by the committee for proprietary 
 medicinal products. 
 (4)</p><p>decision c(1999) 939 should therefore be amended accordingly.</p><p>
 1 oj l 214, 24.8.1993, p. 1. 2 oj l 88, 24.3.1998, p. 7. 3 oj l 55, 11.3.1995, p. 15. 4 oj l 153, 27.5.1998, p. 11.</p><p> iv</p><p> 
 (5)</p><p>the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use, 
 has adopted this decision:</p><p>
 article 1 decision c(1999) 939 is amended as follows: 1. 
 annex i is replaced by annex i to this decision; 
 2. 
 annex iii (b) is replaced by annex ii to this decision. 
 article 2 this decision is addressed to ares-serono (europe) ltd, 24 gilbert street, london w1y 1rj, united kingdom. 
 done at brussels, 20.09.2001.</p><p>for the commission</p><p>
 erkki liikanen</p><p>
 member of the commission</p></section></body></xml>